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Abstract
Background: An advance in the treatment of schizophrenia is the development of long-acting intramuscular 
formulations of antipsychotics, such as olanzapine long-acting injection (LAI). During clinical trials, a post-injection 
syndrome characterized by signs of delirium and/or excessive sedation was identified in a small percentage of patients 
following injection with olanzapine LAI.
Methods: Safety data from all completed and ongoing trials of olanzapine LAI were reviewed for possible cases of this 
post-injection syndrome. Descriptive analyses were conducted to characterize incidence, clinical presentation, and 
outcome. Regression analyses were conducted to assess possible risk factors.
Results: Based on approximately 45,000 olanzapine LAI injections given to 2054 patients in clinical trials through 14 
October 2008, post-injection delirium/sedation syndrome occurred in approximately 0.07% of injections or 1.4% of 
patients (30 cases in 29 patients). Symptomatology was consistent with olanzapine overdose (e.g., sedation, confusion, 
slurred speech, altered gait, or unconsciousness). However, no clinically significant decreases in vital signs were 
observed. Symptom onset ranged from immediate to 3 to 5 hours post injection, with a median onset time of 25 
minutes post injection. All patients recovered within 1.5 to 72 hours, and the majority continued to receive further 
olanzapine LAI injections following the event. No clear risk factors were identified.
Conclusions: Post-injection delirium/sedation syndrome can be readily identified based on symptom presentation, 
progression, and temporal relationship to the injection, and is consistent with olanzapine overdose following probable 
accidental intravascular injection of a portion of the olanzapine LAI dose. Although there is no specific antidote for 
olanzapine overdose, patients can be treated symptomatically as needed. Special precautions include use of proper 
injection technique and a post-injection observation period.
Trial Registration: ClinicalTrials.gov ID; URL: http://http//www.clinicaltrials.gov/: NCT00094640, NCT00088478, 
NCT00088491, NCT00088465, and NCT00320489.
Background
Olanzapine long-acting injection (LAI) is a new depot
antipsychotic formulation consisting of a pamoate salt of
olanzapine that is administered by deep intramuscular
(IM) injection every 2 to 4 weeks. Olanzapine LAI has
been found to be effective for the treatment of schizo-
phrenia in both actively psychotic [1] and stable patients
[2], with a safety profile generally similar to oral olanzap-
ine [2]. However, during clinical trials, a series of cases
was identified in which a cluster of adverse events charac-
terized by post-injection delirium and/or excessive seda-
tion was observed [3,4]. These events are believed to be
associated with accidental intravascular entry of a por-
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tion of the dose, most likely following vessel injury during
the injection process [5].
Accidental intravascular injection is a known risk for all
intramuscularly injected products and is typically
reflected in label warnings. One product with a well-doc-
umented example of a post-injection syndrome following
accidental intravascular injection is penicillin procaine G
[6,7]. When injected intravascularly, the salt formulation
dissociates into its penicillin and procaine components,
resulting in procaine toxicity, which produces a clear
symptomatic presentation known as Hoigne's syndrome.
Other intramuscularly injected products that can result
in noticeable symptoms following accidental intravascu-
lar injection include other long-acting penicillins [8-11],
various anesthetic agents used during dental procedures
(e.g., Septocaine [12]), as well as promethazine [13], bar-
biturates and benzodiazepines [14].
With regard to injectable antipsychotics, all advise in
their labels against intravascular injection. However, the
types of symptoms that might occur or even whether any
identifiable symptoms would occur at all, would depend
on the formulation (e.g., oil-based, salt-based, micro-
sphere-based) and inherent safety profile of the medica-
tion being injected. For long-acting risperidone, for
e x a m p l e ,  r a r e  c a s e s  o f  a n  e m b o l i c - t y p e  r e a c t i o n  h a v e
been reported with the microsphere formulation. There
is recent evidence that a patient with a cardiac malforma-
tion (f. ovale) who experienced an accidental intravascu-
lar injection of long-acting risperidone developed retinal
artery occlusion resulting in persistent blurred vision and
superior field deficit in the right eye. Tang and Weiter
[15] speculate that the microsphere embolized from the
site of injection through the patient's foramen ovale to
the right fundus. For haloperidol decanoate and other oil-
based typical antipsychotic depot formulations, no spe-
cific instances of inadvertent intravascular injection can
be found in the literature.
Olanzapine LAI, as a salt-based formulation, may carry
r i s k  f o r  a  p o s t - i n j e c t i o n  s y n d r o m e  a s  a  r e s u l t  o f  t h e
greater solubility of the salt in blood than in muscle tissue
[5]. Moreover, because of the specific adverse-event pro-
file that accompanies the olanzapine molecule, excessive
amounts of olanzapine entering the blood stream can
result in noticeable symptoms consistent with olanzapine
intoxication, particularly excessive sedation (which could
include coma) and/or delirium. Because of the possibility
of such an occurrence following injection with olanzapine
LAI, it is important for clinicians to have a clear under-
standing of the exact nature of these post-injection syn-
drome events, including what signs and symptoms to
look for in their patients during what time frame, and also
what to expect in terms of clinical progression, manage-
ment, and outcomes following the development of such
an event. Termed "post-injection delirium/sedation syn-
drome" (PDSS) but alternately sometimes referred to as
"post-injection syndrome," the first 30 cases identified are
presented here along with analyses examining the charac-
teristics, timing, and outcomes of these events as well as
an analysis of various patient and injection variables in
order to determine whether there are any risk factors
which might be used to predict the occurrence of PDSS
events.
Methods
This case analysis was based on all 8 olanzapine LAI clin-
i c a l  t r i a l s  t h a t  w e r e  c o n d u c t e d  i n  p a t i e n t s  b e t w e e n
August 2000 and October 2008. These included a single-
dose pharmacokinetic study (n = 134), a 2-month phar-
macokinetic study (N = 9), a 6-month pharmacokinetic
study (N = 282) [16], a receptor occupancy study (N = 14)
[17], an 8-week randomized, placebo-controlled acute
efficacy study (olanzapine LAI n = 304) [1], a 24-week
randomized, oral olanzapine-controlled maintenance
study (olanzapine LAI n = 743) [2], an ongoing 2-year
randomized, oral olanzapine-controlled open-label effec-
tiveness study (olanzapine LAI n = 264) [18], and an
ongoing 6-year open-label extension study (N = 931) [19].
All patients had a DSM-IV or DSM-IV-TR diagnosis of
schizophrenia (n = 2026) or schizoaffective disorder (n =
28) and were between the ages of 18 and 75. Exclusion
criteria included significant suicidal or homicidal risk;
pregnancy or breastfeeding; acute, serious, or unstable
medical conditions; or substance dependency (except
nicotine or caffeine) within the past month. All study pro-
t oc o ls  we r e a p pr o ved by i nst it u ti ona l r eview boa r ds a t
each site. After receiving a complete description of the
study, all patients and/or their authorized legal represen-
tatives provided written informed consent before partici-
pation.
Olanzapine LAI injection procedures
Patients received their injections after completion of all
efficacy and safety assessments at that visit. Injections
were generally administered into alternating sides of the
buttocks from visit to visit, and administrators were
advised not to massage the injection area after injection.
Injections were administered using a 19-gauge 1.5-inch
(or 35-mm) needle; a 2-inch (or 50-mm) needle could be
used for obese patients. Doses ranged from 45 to 405 mg
olanzapine pamoate, and injection intervals could be 2, 3,
or 4 weeks, depending on the specific study. Injections
given at 2-week intervals could not exceed a dose of 300
mg.
Before the PDSS phenomenon was discovered, patients
were observed for 10 to 20 minutes following the injec-
tion before being released. Based on a review of cases, all
ongoing clinical trials were amended in May 2006 to
include a 45-minute post-injection observation periodDetke et al. BMC Psychiatry 2010, 10:43
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and then amended again in August 2006 to include a 3-
hour post-injection observation period.
Variables assessed
In addition to the standard safety assessments collected
for all patients (e.g., physical examination, weight, vital
signs, reporting of adverse events, laboratory analytes),
patients who experienced a PDSS event received other
non-scheduled assessments at the discretion of the inves-
tigator and/or the treating hospital. These could include
sampling of olanzapine plasma concentrations, urine tox-
icology, and other diagnostic procedures.
Statistical methods
All analyses were performed on an intent-to-treat basis
using SAS version 8.2 (SAS Institute, Inc., Cary, N.C.).
Boxplots were created in SigmaPlot version 11 using the
Cleveland method of percentile calculation. Unless other-
wise specified, summary statistics provided are based on
the 30 PDSS events identified as of October 2008. Analy-
ses requiring a locked database relied upon the most
recent interim datalock of the ongoing studies, which
occurred on 30 April 2008, and which includes 29 PDSS
events.
For the purpose of analyses, time of onset of a PDSS
event was defined as the time at which the patient first
experienced noticeable symptoms and/or the time at
which the patient was first witnessed to be experiencing
such symptoms. Time of incapacitation was defined as
the time at which the patient developed symptoms with
the potential to interfere with the patient's ability to seek
assistance (e.g., confusion/disorientation, significant
ataxia, or severe sedation). T ime of hospitalization was
defined as the time at which the patient was sent to the
emergency department or hospital; if this time was
unavailable, time of admission to the emergency depart-
ment or hospital was used instead.
A logistic regression analysis was performed on the
locked database to identify potential risk factors for a
PDSS event. Variables included baseline age, gender, race
(dichotomized as Caucasian or non-Caucasian), geo-
graphic region (dichotomized as United States or outside
the United States), dose, number of previous olanzapine
LAI injections, and body mass index (BMI) for each
patient who experienced a PDSS event and for all who did
not experience such an event. A forward stepwise proce-
dure was used to fit the model. The p-value criteria for
explanatory variables entering the model and staying in
the model were set to 0.20. Risk level was evaluated using
odds ratios with 95% confidence intervals (CI).
Concomitant medication use for all patients was
assessed up to t he time of da ta base lock t o determine
whether any specific medications or classes of medica-
tions posed an increased risk for PDSS. Based on the list
of concomitant medications used by PDSS patients at the
time of the event, medication classes assessed were anti-
cholinergics, antidepressants (all), selective serotonin
reuptake inhibitors (SSRIs), tricyclic antidepressants,
anticoagulants, nonsteroidal anti-inflammatory drugs
(NSAIDs), angiotensin-converting enzyme (ACE) inhibi-
tors, calcium channel blockers, glucose-lowering drugs,
and benzodiazepines/hypnotics. Incidence of concomi-
tant use in patients who experienced PDSS versus
patients who did not was compared using Fisher's exact
test with an alpha of 0.05.
Potential long-term outcomes associated with PDSS
events were assessed by reviewing all spontaneously
reported treatment-emergent adverse events in the
locked database for each PDSS patient after the PDSS
event and up to time of study discontinuation or database
lock.
Results
Exposure and PDSS incidence
Through 14 October 2008, a total of 30 PDSS events
resulting from olanzapine LAI had been reported in 29
patients. Based on approximately 45,000 injections of
olanzapine LAI given to 2054 patients in clinical trials as
of that date, PDSS events had occurred in approximately
0.07% of injections, or 1.4% of patients. Based on the
locked database occurring April 2008, which included 29
PDSS events, 2054 patients had received a total of 41,193
injections of olanzapine LAI with a mean exposure of 14
months (range 2 weeks to 3.8 years) or 20 injections per
patient (range 1 to 100 injections), for a total of 2353.5
patient-years of exposure, and yielding a PDSS rate of 1.2
events per 100 patient-years of exposure.
Description of cases
Case information for each of the 30 PDSS events is sum-
marized in Additional File 1. Events occurred at various
doses and at various cumulative exposure lengths.
Median injection number at which an event occurred was
the 21st injection.
Symptoms
Table 1 summarizes clinical symptoms occurring in at
least two cases and presents the symptoms that occurred
initially in the course of the event versus at any time dur-
ing the event. The most common signs and symptom
types were related to delirium and sedation. Delirium-
related adverse events, such as disorientation, confusion,
ataxia, and dysarthria, were reported in 97% of the
events. Sedation-related adverse events, defined here as
somnolence, sedation, or other change in level of con-
sciousness, were reported in 87% of the events. All 30
cases presented with at least one symptom related to
either delirium or sedation, with 83% of cases resulting inDetke et al. BMC Psychiatry 2010, 10:43
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both delirium- and sedation-related symptoms. Initial
symptoms (i.e., symptoms first noted by the patient,
investigator, or other witness at the onset of the event)
included delirium-related symptoms in 47% of cases and
sedation-related symptoms in 40% of cases. However, in
another 40% of cases, the first symptoms noted did not
include signs of sedation or delirium but were instead
related to general malaise or other symptoms such as
extrapyramidal symptoms (EPS), agitation, anxiety, or
irritability. In those cases, the delirium or sedation devel-
oped subsequent to the initial symptoms.
Onset and progression
Time of onset of symptoms for PDSS events ranged from
0 to 300 minutes post injection, with a mean of 49 min-
utes and a median of 25 minutes post injection. Onset of
the events was predominantly clustered in the 1-hour
post-injection time frame, with 80% of PDSS events
occurring within 1 hour post injection (Figure 1).
Of the 22 cases that met criteria for incapacitation, 21
cases contained enough information to document when
the patient was first observed in an incapacitated state,
with incapacitation defined as the presence of clinically
significant disorientation, ataxia, or sedation such that
the patient would not have been able to seek assistance
on his own. Time from injection to time of first observed
incapacitation ranged from 10 to 300 minutes post injec-
tion, with a mean time of 75 minutes and a median time
of 60 minutes. Thus, median time of incapacitation was
35 minutes later than median time of onset (Figure 2).
Of the 23 events in which the patient was sent to the
emergency department or hospital, the exact time of hos-
pitalization was documented in 17 cases. Time to hospi-
talization ranged from 50 to 420 minutes post injection,
with a mean of 178 minutes and a median of 150 minutes.
Therefore, median time to hospitalization occurred
approximately 2 hours after median time of onset of the
event (Figure 2).
Clinical assessments
Vital signs
Information about vital signs was available for 26 cases.
No clinically significant decreases in vital signs were
observed, with no instances of orthostatic hypotension,
bradycardia, or respiratory depression. Two patients had
clinically significantly increased blood pressure during
the event (Case 24 and Case 27; peaks of 210/110 and
Table 1: Incidence and timing of signs and symptoms of post-injection delirium/sedation syndrome (PDSS) occurring with 
olanzapine long-acting injection
Clinical Symptoms of PDSS Events--Grouped Presented Initially
N (%)
Occurred at Any Time
N (%)
Sedation (e.g., somnolence, sedation, unconsciousness) 12 (40) 26 (87)
Delirium (combined) 14 (47) 29 (97)
Speech Impairment (e.g., dysarthria) 7 (23) 21 (70)
Motor Impairment (e.g., ataxia) 7 (23) 12 (40)
Cognitive Impairment (e.g., confusion, disorientation) 8 (27) 17 (57)
EPS, akathisia, tension or cramps in extremities 3 (10) 7 (23)
Agitation, aggression, irritability, anxiety, restlessnessa 2 (7) 9 (30)
General malaise (e.g., weak, dizzy, felt bad) 19 (63) 20 (67)
Hypertension 1 (3) 2 (7)
Possible seizure/convulsions 0 (0) 2 (7)
Abbreviations: e.g. = for example; EPS = extrapyramidal symptoms; N = number of patients; PDSS = post-injection delirium/sedation 
syndrome.
a Restlessness may also be a manifestation of EPS (akathisia).
Figure 1 Approximate onset time of post-injection delirium/se-
dation syndrome events.
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160/100, respectively) which subsequently responded to
treatment with antihypertensives. Although there were
other cases in which the patient experienced increases in
blood pressure and/or heart rate during the event, these
changes in vital signs were not considered clinically sig-
nificant and were not sustained throughout the event.
Electrocardiograms (ECGs)
Readings of ECGs were obtained for 13 of the 30 PDSS
events. In one of these events (Case 26), right bundle
branch block was identified. This finding was determined
to have resulted from long-standing arterial hypertension
and was not related to the administration of olanzapine
LAI. No other clinically significant ECG changes were
observed for these events.
Electroencephalograms (EEGs)
EEGs were obtained in 4 of the 30 PDSS events (Cases 3,
9, 14, and 28). Cases 3 and 28 had clinical presentations
described by witnesses as convulsive movements, but the
EEG findings did not provide evidence of seizure in either
case. The EEG findings for Cases 3 and 14 were reported
as normal. In Case 9, which involved a patient with diabe-
tes, the EEG showed a generalized slowing of waves cor-
responding with metabolic and/or pharmacological
encephalopathy. In Case 28, an EEG performed approxi-
mately 10 days after the event was reported to be abnor-
mal due to the presence of diffuse disorganization,
consistent with findings seen in other patients with
schizophrenia, but which was not supportive of paroxys-
mal activity or epileptic foci and did not indicate the pres-
ence of characteristic electrographic seizure activity.
Other testing
A computed tomography scan was performed in Cases 2,
3, 5, 9, 13, 14, 24, 28, and 30. In each case, the results of
the computed tomography were negative for any clini-
cally significant findings. A urine and/or blood toxicology
screen was performed in Cases 3, 4, 5, 9, 10, 13, 14, 25,
and 30. In one case (Case 3), the patient was treated with
benzodiazepines upon arriving at the hospital, resulting
in a blood toxicology screen that was positive for benzo-
diazepines. In all other cases, the urine and/or blood tox-
icology screens were negative for alcohol, sedatives, or
illicit substances.
Hospitalization and treatment
In 77% of cases (23/30), the patient was sent to the hospi-
tal at some time during the PDSS event. The majority
(63%) of PDSS events resolved either with no treatment
or were managed with only observation and fluids. In 11
of the 30 PDSS events, the patient was hospitalized and
received medical treatment beyond observation and flu-
ids. In 9 of these 11 events, the patients received various
medications while hospitalized. Although these medica-
tions were often used to treat specific symptoms or con-
comitant medical illness (e.g., biperiden for EPS; insulin
or glibenclamide for elevated blood glucose; enalapril,
captopril, propranolol, or magnesium sulphate for hyper-
tension; antibiotics for infection; benzodiazepines or
other tranquilizers for agitation), some (e.g., lucetam and
cerebrolysin in one case) appear to have been given pro-
phylactically. Six patients received treatment with benzo-
diazepines. Three patients were catheterized: one
because of urinary retention and two prophylactically.
One patient was placed in mechanical restraints because
of agitation. Two patients (Cases 3 and 14) were venti-
lated as a preventative measure following benzodiazepine
administration, one due to apparent seizure and the other
to manage severe agitation so that a computed tomogra-
phy scan could be performed; no respiratory depression
had been noted in either case.
Recovery and post-recovery outcomes
All patients fully recovered from the PDSS event, with
recovery occurring from 1.5 to 72 hours after onset (Fig-
ure 3). In the majority of cases (21/30; 70%), patients con-
tinued to receive further treatment with olanzapine LAI
following the event. At the time of datalock, median
number of additional days of study participation follow-
ing a PDSS event was 184 days, and median number of
subsequent injections received following the event was 9.
To assess for potential long-term outcomes associated
with PDSS events, all adverse events experienced by the
patient after the PDSS event and up to time of study dis-
continuation or database lock were reviewed. Of the 28
patients who experienced a PDSS event prior to the last
database lock, 18 patients had no additional adverse
events of any kind reported following the PDSS event. For
the 10 patients who did have subsequent adverse events
reported, a total of 20 adverse events of any kind were
reported following the PDSS event. Only one patient
Figure 2 Post-injection delirium/sedation syndrome events and 
time to initial onset, incapacitation, and hospitalization. The mid-
dle line inside the box is the median 50th percentile; left border of the 
box is the 25th percentile and right borders of the box is the 75th per-
centile; left whisker is the 10th percentile and right whisker is the 90th 
percentile.
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experienced a second PDSS event (see Cases 5 and 8),
with the second event occurring approximately 6 months
after the first event. Otherwise, a review of the subse-
quent adverse events indicated that, with the exception of
one report of "dry mouth" 1 day after the event for one
patient, patients who experienced a PDSS event and con-
tinued study participation did not subsequently report
any events that appeared to be potentially related to the
P D S S  e v e n t .  E x a m p l e s  o f  t h e s e  u n r e l a t e d  s u b s e q u e n t
adverse events included uterine fibromioma (78 days
after event), erectile dysfunction (192 days after event),
pharingitis (379 days after event), and psychotic exacer-
bation (659 days after event). In addition, the absolute
number of adverse events overall did not appear to
increase following a PDSS event compared with prior to
the PDSS event. Median number of adverse events expe-
rienced by patients prior to the PDSS event was one;
median number of adverse events reported by patients at
any time after the PDSS event was zero.
Post-recovery dosing
In 13 cases, there was no change in dose following the
PDSS event. In 8 cases, the olanzapine LAI dose was
decreased at the next injection following the PDSS event.
No patients received oral olanzapine supplementation
following the PDSS event.
Analysis of risk factors
N o  c l e a r  r i s k  f a c t o r s  f o r  P D S S  w e r e  i d e n t i f i e d .  O f  t h e
variables assessed in the logistic regression analysis, only
three met criteria to enter and remain in the model (p <
0.20): BMI (p = 0.033), age (p = 0.035), and dose (p =
0.126). However, the odds ratios clustered around 1.0,
indicating a small incremental increase in risk for each
unit decrease in BMI (odds ratio = 0.92 [95% CI 0.86-
0.99] and for each year increase in age (odds ratio = 1.03
[95% CI 1.00-1.07], but no significant increase in risk
based on dose (odds ratio = 1.00 [95% CI 1.00-1.01]).
No concomitant medications were identified as risk
factors. There was no class of drugs with statistically sig-
nificantly higher incidence of use among patients experi-
e ncin g PDS S c om pa r ed wit h pa ti en ts no t e x pe rie ncing
PDSS. Statistically significant differences were noted with
respect to three specific medications (escitalopram, p =
0.026; fluvoxamine, p = 0.040; oxaprozin, p = 0.014); how-
ever, those findings appeared driven by the very small
numbers of patients using those medications in the total
sample (N's of 19, 3, and 1, respectively) and are likely
spurious.
Discussion
Incidence
During clinical trials of olanzapine LAI, 30 post-injection
delirium/sedation syndrome cases occurred in 29
patients from August 2000 to October 2008. The inci-
dence of PDSS events was 0.07% of injections or approxi-
mately one event per 1400 injections. To put this
observed rate into clinical context, a clinic with 60
patients receiving an injection every 2 weeks might
expect approximately 1 event per year; a clinic with 60
patients receiving an injection every 4 weeks might
expect 1 event every 2 years.
Symptoms and identification of cases
Symptoms of PDSS were consistent with some of those in
oral olanzapine overdose, including dizziness, confusion,
disorientation, slurred speech, altered gait, weakness,
muscle spasms, possible seizure, and varying degrees of
sedation. It should be noted that not all of the symptoms
reported with oral olanzapine overdose were seen in
patients during PDSS events. For example, neither ortho-
static hypotension nor respiratory depression were
reported. In many instances, the clinical picture of PDSS
was described as similar to that of alcohol intoxication.
Overall, the syndrome is best characterized and identified
by a convergence of symptoms related to transient delir-
ium and/or excessive sedation. Based on these findings
from the clinical trials, a working case definition is pro-
posed in Appendix A.
Not all of the cases initially began with symptoms of
sedation or delirium but instead began with nonspecific
symptoms of malaise (e.g., dizziness, weakness, not feel-
ing well). Therefore, it will be important for healthcare
providers and patients to be alert for the development of
any of these potential early warning signs in order to
identify PDSS events at the earliest possible time to
ensure that appropriate measures are taken to maintain
the patient's safety.
Figure 3 Approximate time to recovery from post-injection delir-
ium/sedation syndrome events.
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Onset and progression
Data regarding time of onset indicated that the risk of
occurrence of a PDSS event was greatest within the first
hour, although events also occurred rarely (< 1 in 1,000
injections) between 1 and 3 hours and very rarely (< 1 in
10,000 injections) after 3 hours. Although PDSS events
can be serious in nature, events have not been character-
ized by a sudden onset of incapacitation but usually
began with milder symptoms that then progressed in
number and/or severity. This gradual onset thus allows
time for those around the patient to identify the syn-
drome and respond accordingly.
The duration of the PDSS event has varied. Although
milder events took from 1.5 to 3 hours to resolve, most
events required about 24 to 72 hours to resolve fully. For
the 7 patients who lost consciousness at any time, the lon-
gest period of unconsciousness was 12 hours.
Treatment and outcomes
A l t h o u g h  m o s t  p a t i e n t s  w e r e  h o s p i t a l i z e d  d u r i n g  t h e
event, a majority of PDSS events either resolved with no
treatment or were managed with only observation and
fluids. When active treatments were given, this tended to
be in response to the development of specific symptoms--
either related or unrelated to PDSS, such as EPS, elevated
blood glucose, hypertension, infection, or agitation. The
majority of patients who experienced a PDSS event con-
tinued to receive further injections of olanzapine LAI.
Those who continued to participate in the studies did not
require oral antipsychotic supplementation following the
event and were able to receive their next injections of
olanzapine LAI at their next regularly scheduled injection
visits. A review of adverse events experienced by patients
in the days, months, and years after the PDSS event sup-
ports the conclusion that patients recovered from the
event with no lingering or permanent sequelae.
Risk factors
No concomitant medications or precipitating events
could be identified which might predispose a patient
toward the occurrence of PDSS. However, there appears
to be limited evidence suggesting that individual patient
factors related to patients' general health and physical sta-
tus could incrementally increase the risk of an event.
Regression analyses indicated that lower BMI and/or
higher age could increase risk somewhat. Counterbalanc-
ing these statistical findings, it is important to note that
PDSS events occurred in patients at many different ages
and BMIs. Therefore, younger age and higher BMI do not
prevent the occurrence of PDSS, nor do higher age and
lower BMI necessarily predict its occurrence. Instead,
PDSS can potentially occur at any injection in any
patient, suggesting the need to monitor all patients for its
possible occurrence.
As discussed by McDonnell et al. [5], the probable
mechanism most likely involves accidental entry of the
medication into the blood stream following blood vessel
injury during the injection process. The similarity in inci-
dence of olanzapine LAI PDSS (0.07% of injections) to
that of Hoigne's syndrome following accidental intravas-
cular injection of penicillin procaine G (0.08% of injec-
tions) [6] suggests that these findings may be
approximating the naturally occurring background rate
for accidental direct or indirect intravascular injection
during any intramuscular injection process.
Nevertheless, another finding which suggests that there
may also be individual patient factors which could affect
the occurrence of PDSS is the fact that one patient in the
clinical trials experienced this event twice. Examination
of medical history and concomitant medications indi-
cated that this patient had a number of chronic condi-
tions (including diabetes, arthritis, alcoholism, and
hypertension) and may have been in poorer general
health than the other PDSS patients, although such con-
ditions are not at all uncommon in patients with schizo-
phrenia and are certainly represented among the patients
who did not experience PDSS. It is important to note that
McDonnell et al. [5] found olanzapine pamoate to be sig-
nificantly more soluble in blood, such that accidental
contact of the medication with a large quantity of blood
may produce higher than expected olanzapine plasma
concentrations in a manner that would be consistent with
the clinical presentation and timing of the symptoms of
PDSS. Thus, a patient who was more prone to bleeding
and/or vessel injury might theoretically be at greater risk
for this accidental occurrence. Chronic salicylate usage
has been associated with increased clotting time and risk
of bleeding [20-22], as has alcoholism [23,24]. Also,
chronic diabetes can result in vascular fragility [25,26].
Thus, any or all of these factors may have created a pre-
disposition toward excessive bleeding and/or increased
likelihood of vessel injury in this patient. Beyond the idio-
syncratic situation with this particular patient, the
hypotheses generated by this case may converge with the
statistical findings of greater age and lower BMI as weak
risk factors for PDSS if one assumes that greater age is
associated with a higher likelihood of poorer general
health and likelihood of vascular fragility and if lower
B M I  i s  a s s o c i a t e d  w i t h  h i g h e r  l i k e l i h o o d  o f  v a s c u l a r
injury during the injection. However, none of these
h y p o t h e s e s  h a v e  b e e n  a b l e  t o  b e  c o n f i r m e d .  F u r t h e r
research on a larger number of cases is needed to explore
more fully the possibility of specific risk factors.
Risk management
Because PDSS events likely involve a portion of the olan-
zapine LAI dose coming into contact with blood, and
because accidental intravascular administration is aDetke et al. BMC Psychiatry 2010, 10:43
http://www.biomedcentral.com/1471-244X/10/43
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known risk of intramuscularly administered drugs, use of
appropriate injection technique is a necessary precaution.
The injection administrator should aspirate for several
seconds to ensure that no blood appears before injecting
the medication. If any blood is aspirated into the syringe,
the clinician should discard the syringe, reconstitute a
new vial of olanzapine LAI, and inject the medication
into the alternate buttock deep into the gluteal muscle.
Nursing texts and scientific literature also state that the
ventrogluteal location is the preferred injection site for
intramuscular injections [27,28]. The rationale for this
recommendation is that the ventrogluteal site is less likely
to access the sciatic nerve or a major blood vessel; this
site also maximizes the likelihood of achieving an intra-
muscular injection, as opposed to an accidental subcuta-
neous injection.
Because proper injection technique does not guarantee
that a blood vessel injury has not occurred during the
injection process, it is therefore necessary to observe the
patient following each injection. Following each injection
of olanzapine LAI, healthcare personnel should observe
the patient at the healthcare facility for at least 3 hours for
signs and symptoms consistent with olanzapine overdose
and should confirm that the patient is alert, oriented, and
absent of any signs and symptoms of overdose prior to
discharge. Because of the risk that a PDSS event could
still occur following this 3-hour period, patients will need
to have someone go with them to their destination upon
leaving the facility after the observation period. They
s h o u l d  a l s o  be  a d v i s e d  t o  be  v i g i l a n t  f o r  s y m p t o m s  o f
post-injection adverse reactions, should be able to obtain
medical assistance if needed, and should not drive or
operate heavy machinery for the remainder of the day of
the injection. These precautions are summarized in
Appendix B. Note that if a PDSS event is suspected, close
monitoring and supervision of the patient should con-
tinue until examination indicates that signs and symp-
toms have resolved. Also, if parenteral benzodiazepines
are required for the management of post-injection
adverse reactions, careful evaluation of clinical status for
excessive sedation and cardiorespiratory depression are
recommended.
Conclusion
In conclusion, post-injection delirium/sedation syn-
drome has occurred following 0.07% of injections of olan-
zapine LAI, with 1.2 events occurring per 100 patient
years of exposure. These events are readily identifiable
and have been successfully managed during the clinical
trials. All patients have recovered with no lingering or
permanent sequelae, and most have elected to continue
receiving treatment with olanzapine LAI and have not
had additional PDSS events. However, because of the
need for a 3-hour post-injection observation period as
well as additional precautions for the remainder of the
day of the injection, it will be important for clinicians and
their patients to weigh the risks and benefits of treatment
with olanzapine LAI and to determine ahead of time
whether the patient will be able to make arrangements in
order to comply with the necessary precautions.
Appendix A
Proposal for Working Case Definition of Olanzapine Long-
Acting Injection Post-Injection Delirium/Sedation 
Syndrome (PDSS)
Criteria 1 through 4 must be met for a clinical diagnosis
of post-injection delirium/sedation syndrome.
1. One or both of the conditions listed in (a) and (b):
a. A minimum of 1 sign or symptom from at least 3 of 
the following symptom clusters consistent with olan-
zapine* overdose with one or more of at least moder-
ate severity.
i. Sedation/somnolence
ii. Delirium/confusion/disorientation/other cog-
nitive impairment
iii. Dysarthria/other speech impairment
iv. Ataxia/other motor impairment
v. Extrapyramidal symptoms
vi. Agitation/irritability/anxiety/restlessness
vii. Dizziness/weakness/general malaise
viii. Seizure
b. Any one of the following signs and symptoms such 
that patient is: 
unarousable
unconscious
stuporous
comatose
* Other signs and symptoms not listed under 1a may 
occur with olanzapine overdose but are not consid-
ered criteria for PDSS. See olanzapine prescribing 
information.
2. Condition develops within 24 hours of an olanzapine
long-acting injection.
3. Condition cannot be explained by a significant dose
increase of olanzapine long-acting injection, initiation or
addition of oral olanzapine or other sedating medication,
or new exposure to olanzapine long-acting injection.
4. Underlying medical conditions have been ruled out,
including concomitant substance use or abuse.
Appendix B
Safety Precautions for Each Administration of Olanzapine 
Long-Acting Injection
Before the Injection
• Determine that the patient will not travel alone to their
post-injection destinationDetke et al. BMC Psychiatry 2010, 10:43
http://www.biomedcentral.com/1471-244X/10/43
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During the Injection
• Aspirate the syringe for several seconds following inser-
tion of the needle into the muscle to ensure that no blood
appears before injecting the medication. If any blood is
aspirated into the syringe, discard the syringe, reconsti-
tute a new vial of olanzapine LAI, and inject into the
alternate side of the buttock.
After the Injection
• Patients should be observed in a healthcare facility by
appropriately qualified personnel for at least 3 hours for
signs and symptoms consistent with olanzapine overdose.
Before Leaving the Healthcare Facility
• Confirm the patient is alert, oriented, and without signs
or symptoms of post-injection delirium/sedation syn-
drome (PDSS) event.*
• Advise patients to be vigilant for symptoms of a PDSS
event for the remainder of the day and be able to obtain
medical assistance if needed.
After Leaving the Healthcare Facility
• Patients should not drive or operate machinery for the
remainder of the day.
* If post-injection delirium/sedation syndrome is sus-
pected, close medical supervision and monitoring should
continue until examination indicates that signs and
symptoms have resolved. If parenteral benzodiazepines
are required for the management of post-injection
adverse events, careful evaluation of clinical status for
excessive sedation and cardiorespiratory depression is
recommended.
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